Latest Period
Q4 2025
Security Snapshot
4D Molecular Therapeutics, Inc. - Common Stock (FDMT) Institutional Ownership
CUSIP: 35104E100
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
149
Shares (Excl. Options)
53,383,257
Price
$7.50
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- FDMT on Nasdaq
- Shares outstanding
- 50,943,214
- Price per share
- $9.84
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 53,383,257
- Total reported value
- $400,363,706
- % of total 13F portfolios
- 0%
- Share change
- +13,991,310
- Value change
- +$104,755,232
- Number of holders
- 149
- Price from insider filings
- $9.84
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- FDMT - 4D Molecular Therapeutics, Inc. - Common Stock is tracked under CUSIP 35104E100.
- 149 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 149 to 40 between Q4 2025 and Q1 2026.
- Reported value moved from $400,363,706 to $28,610,411.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 149 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 35104E100?
CUSIP 35104E100 identifies FDMT - 4D Molecular Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 35104E100:
Significant Owners of 4D Molecular Therapeutics, Inc. - Common Stock (FDMT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 10% | 0% | $45,959,629 | +$9,546,222 | 5,847,281 | +26% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $44,910,877 | +$9,031,022 | 5,713,852 | +25% | RA Capital Management, L.P. | 31 Dec 2025 |
| JANUS HENDERSON GROUP PLC | 10% | +28% | $48,852,550 | +$5,691,163 | 5,247,151 | +13% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| GOLDMAN SACHS GROUP INC | 7.5% | -21% | $33,688,569 | -$1,079,634 | 4,286,077 | -3.1% | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2025 |
| Novo Holdings A/S | 6.4% | -5.7% | $28,694,793 | +$3,739,293 | 3,650,737 | +15% | Novo Holdings A/S | 31 Dec 2025 |
| BlackRock, Inc. | 6.6% | -15% | $26,613,959 | -$4,803,137 | 3,062,596 | -15% | BlackRock, Inc. | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 1.5% | -82% | $2,202,200 | -$7,393,006 | 677,600 | -77% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2025 |
| Deep Track Capital, LP | 1.3% | $1,982,175 | 609,900 | Deep Track Capital, LP | 31 Dec 2024 |
As of 31 Dec 2025, 149 institutional investors reported holding 53,383,257 shares of 4D Molecular Therapeutics, Inc. - Common Stock (FDMT). This represents 105% of the company’s total 50,943,214 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of 4D Molecular Therapeutics, Inc. - Common Stock (FDMT) together control 92% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | 5,653,211 | +24% | 0.44% | $42,399,083 |
| JANUS HENDERSON GROUP PLC | 9.1% | 4,635,875 | +164% | 0.02% | $34,726,165 |
| BVF INC/IL | 9.1% | 4,629,289 | 0% | 1.2% | $34,719,668 |
| GOLDMAN SACHS GROUP INC | 8.4% | 4,302,905 | +4.2% | 0% | $32,271,789 |
| BlackRock, Inc. | 8% | 4,064,876 | +5.1% | 0% | $30,486,573 |
| NOVO HOLDINGS A/S | 7.2% | 3,650,737 | +83% | 2.1% | $27,380,528 |
| VANGUARD GROUP INC | 6.1% | 3,093,527 | +20% | 0% | $23,201,453 |
| STATE STREET CORP | 5.3% | 2,688,880 | +198% | 0% | $20,166,600 |
| ARMISTICE CAPITAL, LLC | 3.8% | 1,936,000 | +77% | 0.36% | $14,520,000 |
| FEDERATED HERMES, INC. | 3.2% | 1,609,482 | +0.92% | 0.02% | $12,071,116 |
| Point72 Asset Management, L.P. | 3% | 1,539,860 | 0.02% | $11,548,950 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.4% | 1,235,156 | +606% | 0.01% | $9,263,670 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,012,025 | +11% | 0% | $7,591,665 |
| Evergreen Quality Fund GP, Ltd. | 1.9% | 951,474 | 0.14% | $7,136,055 | |
| BANK OF AMERICA CORP /DE/ | 1.6% | 832,591 | +1.6% | 0% | $6,244,433 |
| DEUTSCHE BANK AG\ | 1.4% | 704,207 | +30% | 0% | $5,281,553 |
| MORGAN STANLEY | 1.3% | 672,695 | -20% | 0% | $5,045,215 |
| RENAISSANCE TECHNOLOGIES LLC | 1% | 512,900 | +64% | 0.01% | $3,846,750 |
| Parkman Healthcare Partners LLC | 0.99% | 503,431 | +152% | 0.36% | $3,775,733 |
| ArrowMark Colorado Holdings LLC | 0.95% | 485,389 | -3.7% | 0.08% | $3,640,418 |
| RAYMOND JAMES FINANCIAL INC | 0.94% | 477,505 | +1.3% | 0% | $3,581,288 |
| RTW INVESTMENTS, LP | 0.93% | 475,737 | 0.04% | $3,568,028 | |
| BAKER BROS. ADVISORS LP | 0.93% | 475,737 | 0.02% | $3,568,028 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.69% | 353,391 | +16% | 0% | $2,650,433 |
| TWO SIGMA INVESTMENTS, LP | 0.66% | 337,503 | +23% | 0% | $2,531,273 |
Institutional Holders of 4D Molecular Therapeutics, Inc. - Common Stock (FDMT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 3,079,681 | $28,610,411 | +$2,690,886 | $9.31 | 40 |
| 2025 Q4 | 53,383,257 | $400,363,706 | +$104,755,232 | $7.50 | 149 |
| 2025 Q3 | 39,480,388 | $343,063,699 | -$4,201,365 | $8.69 | 129 |
| 2025 Q2 | 40,369,426 | $149,859,289 | -$9,235,482 | $3.71 | 117 |
| 2025 Q1 | 43,058,381 | $139,823,044 | -$22,403,324 | $3.23 | 122 |
| 2024 Q4 | 46,814,824 | $260,642,119 | -$79,332,651 | $5.57 | 140 |
| 2024 Q3 | 57,948,767 | $626,374,639 | -$34,446,524 | $10.81 | 135 |
| 2024 Q2 | 57,307,189 | $1,203,018,791 | +$3,520,347 | $20.99 | 138 |
| 2024 Q1 | 56,228,706 | $1,790,823,856 | +$449,592,828 | $31.86 | 146 |
| 2023 Q4 | 42,433,937 | $859,819,319 | +$24,792,782 | $20.26 | 111 |
| 2023 Q3 | 41,913,779 | $533,559,212 | +$5,221,810 | $12.73 | 110 |
| 2023 Q2 | 41,248,927 | $745,334,512 | +$197,052,931 | $18.07 | 100 |
| 2023 Q1 | 30,404,028 | $522,337,328 | +$34,968,755 | $17.19 | 94 |
| 2022 Q4 | 28,011,571 | $622,110,124 | +$47,681,640 | $22.21 | 97 |
| 2022 Q3 | 26,181,987 | $210,496,945 | +$1,974,268 | $8.04 | 84 |
| 2022 Q2 | 26,027,061 | $181,670,139 | -$2,172,042 | $6.98 | 86 |
| 2022 Q1 | 26,134,053 | $395,189,957 | +$20,420,485 | $15.12 | 76 |
| 2021 Q4 | 24,702,968 | $541,790,297 | +$81,054,878 | $21.94 | 77 |
| 2021 Q3 | 18,711,908 | $504,667,012 | +$57,523,278 | $26.97 | 61 |
| 2021 Q2 | 16,612,608 | $400,026,000 | +$731,531 | $24.08 | 54 |
| 2021 Q1 | 15,384,514 | $664,816,567 | +$34,097,345 | $43.38 | 63 |
| 2020 Q4 | 14,593,004 | $602,432,000 | +$578,482,000 | $41.45 | 51 |